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Vaccine implementation reduces inequity
While Streptococcus pneumoniae was first described 
over 100 years ago, it wasn’t until 50 years later that 
the first vaccines—pneumococcal polysaccharide 
vaccines at the time—were available.1 The use of 
the pneumococcal polysaccharide vaccines had an 
important effect on pneumococcal infections, especially 
in adults.1 However, that effect was hampered because 
the number of circulating serotypes was higher than 
initially anticipated, with about a hundred serotypes 
currently known.2 Moreover, the effect of polysaccharide 
vaccines is unfortunately reduced in some target 
groups, particularly young children, who react poorly to 
polysaccharides.1,3,4
In the 1990s and early 2000s, pneumococcal conjugate 
vaccines (PCV) emerged.1,4 By conjugating proteins to 
the different capsular polysaccharides, a T-cell immune 
reaction is elicited, resulting in sufficient immune 
response in children. However, the number of serotypes 
that can be conjugated to the capsular polysaccharides 
is limited in the available formulations. The initial 
seven-valent vaccine was later replaced with higher 
valent vaccines. The effects of PCVs, especially higher 
valent PCVs, on invasive pneumococcal disease,3,5,6 
respiratory infections,5,7 nasopharyngeal carriage,6,8 and 
acute otitis media5,9 have been widely published and are 
indisputable.4 Nevertheless, the global burden of disease 
of pneumococcal infections is still enormous, with a high 
annual global mortality, especially in children in lower-
income countries.1,6
Nasopharyngeal carriage is thought to be a prerequisite 
for clinically symptomatic pneumococcal infections and 
carriage rates are especially high in young children.3,4,6,8 
Therefore, studying pneumococcal nasopharyngeal 
carriage can give important information on circulating 
serotypes in the community, potential invasiveness, 
and microbial resistance patterns.4,6 PCVs have a clear 
effect on the nasopharyngeal carriage, with a decrease 
of horizontal spread and a distinct reduction in vaccine-
serotype pneumococci.6,8 This decrease in horizontal 
spread can also lead to an increased herd effect, which 
adds to the primary effect of the vaccines. However, 
despite the effects on vaccine-serotype pneumococci, 
the total pneumococcal carriage rates are either not 
affected or marginally affected, as vaccine-serotype 
pneumococci are replaced by non-vaccine serotypes.2–5 
As long as these non-vaccine serotypes colonising the 
nasopharynx are less invasive, cause less pneumococcal 
infections, and are susceptible to antibiotics, the overall 
effects of the vaccine programmes should be regarded 
as extremely successful. Nevertheless, it is obviously 
important to closely monitor any changes in the 
nasopharyngeal carriage of pneumococcal serotypes 
because new serotypes, possibly invasive and antibiotic 
resistant, might emerge and pose a threat for clinically 
significant infections in the future.4,6
In the Lancet Global Health, Eileen M Dunne 
and colleagues10 report the results of four annual 
carriage surveys in Fiji on the effect of ten-valent 
PCV introduction in Fiji. They described a decline in 
adjusted prevalences (2015 vs 2012) in pneumococcal 
nasopharyngeal carriage of vaccine serotypes in 
5–8-week-old infants (0·56, 95% CI 0·34–0·93), 
12–23-month-old children (0·34, 0·23–0·49), 2–6-year-
old children (0·47, 0·34–0·66), and their caregivers 
(0·43, 0·13–1·42) 3 years after PCV introduction. 
These results support a strong herd protection in the 
community, as evident in the carriage decline described 
in infants too young to be vaccinated. This important 
finding adds to earlier publications on the herd effect of 
PCV, in both children and older populations.5,7,8
An important message of the study by Dunne 
and colleagues is the unambiguous effect of PCV 
introduction on carriage of vaccine serotypes on both 
the Indigenous population and the population of 
Indian descent in Fiji. It is well described that the rate 
of pneumococcal nasopharyngeal carriage is different 
in various populations and age groups, often high in 
Indigenous populations, low-income communities, 
crowed households, and low socioeconomic status.3,4,8 
This translates into higher risk of infections caused by 
pneumococcus in these groups, adding to this inequity.
This study from Fiji reiterates the knowledge that 
initiating vaccination programmes can not only 
decrease severe infections, but also reduce inequity and 
disparity. That is important!
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